# Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

> **NCT04514393** · PHASE2 · UNKNOWN · sponsor: **Huiqiang Huang** · enrollment: 33 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma
- PCNSL
- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Ibrutinib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04514393
- **Lead sponsor:** Huiqiang Huang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-10
- **Primary completion:** 2022-09-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2022-04-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04514393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04514393, "Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04514393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*